Skip to main content

Advertisement

Table 1 SATB1-expression in relation to clinicopathological parameters and SATB2-expression

From: Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma

  Pancreatobiliary type Intestinal type
  SATB1 - n = 85 SATB1 + n = 21 SATB 1 missing n = 2 p-value SATB1- n = 47 SATB1+ n = 16 SATB1 missing n = 2 p-value
Age, years, M (IQR) 66 (61–72) 69 (64–74) 2 0.681 67 (62–72) 67 (57–70) 2 0.981
Sex, n (%)     0.469     0.777
Women 41 (48%) 8 (38%) 2   26 (55%) 8 (50%) 1  
Men 44 (52%) 13 (62%)    21 (45%) 8 (50%) 1  
Tumour origin, n (%)     0.852     0.487
Duodenum      12 (26%) 2 (13%)   
Ampulla Intestinal type      35 (74%) 14 (87%) 2  
Ampulla Pancreatobiliary type 16 (19%) 3 (14%)       
Distal bile duct 34 (40%) 10 (48%) 1      
Pancreas 35 (41%) 8 (38%) 1      
Tumour size, mm, M (IQR) 30 (25–35) 28 (21–30) 2 0.799 25 (15–40) 30 (24–40) 2 0.848
Differentiation grade, n (%)     0.211     0.148
Well-moderate 34 (40%) 5 (24%) 1   26 (55%) 5 (31%) 1  
Poor 51 (60%) 16 (76%) 1   21 (45%) 11 (69%) 1  
T-stage, n (%)     1.000     0.860
T1 2 (2%) 0 1   4 (9%) 0 1  
T2 8 (9%) 2 (10%)    8 (17%) 3 (19%) 1  
T3 61 (72%) 16 (76%) 1   18 (38%) 7 (44%)   
T4 14 (16%) 3 (14%)    17 (36%) 6 (37%)   
N-stage, n (%)     0.421     0.564
N0 25 (29%) 4 (19%) 2   26 (55%) 7 (44%) 2  
N1-N2 60 (71%) 17 (81%)    21 (45%) 9 (56%)   
Margins, n (%)     1.000     1.000
R0 5 (6%) 1 (5%) 1   13 (28%) 4 (25%) 1  
R1-Rx 80 (94%) 20 (95%) 1   34 (72%) 12 (75%) 1  
Perineural growth, n (%)     0.232     0.533
No 20 (24%) 2 (10%) 1   34 (72%) 10 (62%) 1  
Yes 65 (76%) 19 (90%) 1   13 (28%) 6 (38%) 1  
Invasion of lymphatic vessels, n (%)     0.792     0.081
No 25 (29%) 7 (33%) 1   25 (53%) 4 (25%)   
Yes 60 (71%) 14 (67%) 1   22 (47%) 12 (75%) 2  
Invasion of blood vessels, n (%)     0.070     0.594
No 60 (71%) 10 (48%) 1   44 (94%) 14 (87%) 2  
Yes 25 (29%) 11 (52%) 1   3 (6%) 2 (13%)   
Growth in peripancreatic fat, n (%)     0.760     0.545
No 18 (21%) 3 (14%) 2   32 (68%) 9 (56%) 2  
Yes 67 (79%) 18 (86%)    15 (32%) 7 (44%)   
SATB2, n (%)     0.092     0.422
Negative 84 (99%) 18 (90%) 2   40 (89%) 13 (81%) 0  
Positive 1 (1%) 2 (10%) 0   5 (11%) 3 (19%) 0  
Missing 0 1 0   2 0 2  
Adjuvant chemotherapy, n (%)     0.739     0.301
No adjuvant 41 (48%) 9 (43%) 1   35 (74%) 10 (63%) 2  
5FU-analogue 5 (6%) 3 (14%)    4 (9%) 1 (6%)   
Gemcitabine 35 (41%) 9 (43%)    5 (11%) 2 (13%)   
Gemcitabine + capecitabine 1 (1%) 0 1   0 1 (6%)   
Oxaliplatin +5-FU analogue 1 (1%) 0    3 (6%) 1 (6%)   
Gemcitabine + oxaliplatin 2 (2%) 0    0 1 (6%)   
Recurrence     0.250     0.658
No 16 (19%) 3 (14%) 1   27 (57%) 7 (44%) 1  
Yes, local only 25 (29%) 3 (14%) 1   3 (6%) 1 (6%)   
Yes, non-local 44 (52%) 15 (71%)    17 (36%) 8 (50%) 1  
Included in survival analyses     1.000     1.000
Yes 84 (99%) 21 (100%) 0   45 (96%) 16 (100%) 0  
No 1 (1%) 0 2   2 (4%) 0 2  
  1. There were no significant associations between SATB1-expression, clinicopathological characteristics and SATB2-expression.